CDK9 and cancer: Multiple studies using small molecule inhibitors and RNA interference have demonstrated that oncogenic transcription driven by CDK9 increases the survival and proliferation of cancer cells (Chen et al., 2005; Huang et al., 2014) and hence is continuously targeted for cancer treatment (Baker et al., 2016; Morales and Giordano, 2016; Rahaman et al., 2016).